Medical and Scientific News
-
Hemophilia A gene therapy approved in Europe but possibly delayed in the U.S.
Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A...
-
Hemophilia B gene therapy approved by U.S. FDA
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene...
-
CHS strongly supports CBS’ plasma initiative
Montreal, September 7, 2022 – “The Canadian Hemophilia Society (CHS) strongly supports Canadian Blood Services’ plans to work with a leading company in the plasma...
-
Return of Octostim spray delayed until late 2024
In a letter to the European Haemophilia Consortium dated May 31, 2022, Ferring Pharmaceuticals informed the bleeding disorder community that Octostim (desmopressin) Nasal Spray 1.5...
-
Novel treatments in bleeding disorders: The EHC November Review
CLICK HERE to access the November 2021 review of novel treatments in haemophilia and other bleeding disorders by the European Haemophilia Consortium.